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Summary Infectious diseases cause the suffering of hundreds of millions of people, especially in tropical and
subtropical areas. Effective, affordable and easy-to-use medicines to ®ght these diseases are nearly absent.
Although science and technology are suf®ciently advanced to provide the necessary medicines, very few
new drugs are being developed. However, drug discovery is not the major bottleneck. Today's R&D-
based pharmaceutical industry is reluctant to invest in the development of drugs to treat the major
diseases of the poor, because return on investment cannot be guaranteed. With national and international
politics supporting a free market-based world order, ®nancial opportunities rather than global health
needs guide the direction of new drug development. Can we accept that the dearth of effective drugs for
diseases that mainly affect the poor is simply the sad but inevitable consequence of a global market
economy? Or is it a massive public health failure, and a failure to direct economic development for the
bene®t of society? An urgent reorientation of priorities in drug development and health policy is needed.
The pharmaceutical industry must contribute to this effort, but national and international policies need
to direct the global economy to address the true health needs of society. This requires political will, a
strong commitment to prioritize health considerations over economic interests, and the enforcement of
regulations and other mechanisms to stimulate essential drug development. New and creative strategies
involving both the public and the private sector are needed to ensure that affordable medicines for
today's neglected diseases are developed. Priority action areas include advocating an essential medicines
R&D agenda, capacity-building in and technology transfer to developing countries, elaborating an
adapted legal and regulatory framework, prioritizing funding for essential drug development and
securing availability, accessibility, distribution and rational use of these drugs.
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Introduction
Infectious diseases kill 14 million people each year.
More than 90% of these deaths occur in developing
countries (WHO 1999). In addition to the HIV/AIDS
pandemic, respiratory infections, malaria and tubercu-
losis are the leading causes of death and morbidity in
Africa, Asia and South America ± accounting for four-
®fths of the world's population. Access to treatment for
these diseases is problematic because medicines are
unaffordable, have become ineffective, or are not
adapted to local conditions of use. For several other
diseases common in the developing world, medicines are
simply non-existent.
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understanding of the molecular and cellular basis of life,
and this has resulted in increasingly sophisticated thera-
peutic strategies to cure a wide variety of diseases,
including lifestyle diseases such as obesity and impotence.
In contrast, despite the enormous burden of disease in
poor countries, drug discovery and development targeted
at tropical diseases has ground to a standstill (Pe Âcoul
et al. 1999). Only a small fraction of the total worldwide
expenditure on health research and development
(estimated at US$50±60 billion a year) is devoted to the
development of such medicines (Global Forum for Health
Research 1999). With the emergence of a free market-
based world order, pro®t prospects rather than global
health needs guide the direction of new drug develop-
ment. The adverse public health consequences of this
evolution for the tropical world have been grave
(Trouiller 1996).
This paper ®rst discusses the key factors that deter the
pharmaceutical industry from conducting research and
development (R&D) into these Neglected Diseases and
then outlines possible new strategies and approaches to
ensure that new and affordable medicines could be
developed.
Priority setting in drug development
Drug development is a complex, expensive and time-
consuming activity, subject to stringent regulations. Today,
drug development is con®ned almost exclusively to a
consolidated and highly competitive multinational drug
industry driven by pro®t and subject to the laws of a
globalized market economy. Market forces inevitably skew
the direction of drug R&D towards those diseases and
patients (customers) that assure the highest ®nancial
returns (Sachs 1999). In 1999, North America, Europe and
Japan accounted for 82.4% of the world pharmaceutical
market (valued at US$ 337 billion), while Africa and Asia,
representing more than two-thirds of the world population,
only accounted for 10.6% of the market (Figure 1) (IMS
1999). Despite the global public health relevance of
infectious diseases, their predominant distribution in poor
countries is perceived as a major disincentive to invest in
the discovery and development of new treatments for these
illnesses. Indeed, less than 1% of the 1223 new medicines
launched on the international market between 1975 and
1997 were destined speci®cally for tropical communicable
diseases (Trouiller & Olliaro 1999). These appalling
statistics illustrate why these diseases, which include major
killers such as malaria, justi®ably warrant the term
`Neglected Diseases'.
Current barriers to drug development
for neglected diseases
Costs of R&D
The most frequently voiced argument to explain or justify
the pharmaceutical industry's near-zero investment
in drugs for tropical infectious diseases is the high
Figure 1 Pharmaceutical market
distribution compared to world population
distribution.
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®nancial return. The estimates of the true costs of R&D,
however, remain highly controversial. In one study, the full
after-tax cost of developing a new drug was estimated by
the US Of®ce of Technology Assessment at approximately
US$ 312 million (in 1997 dollars) (Kettler 1999). Other
estimates range between US$ 160 and 450 million (DiMasi
et al. 1994; Grabowsky & Vernon 1994). These estimates
are based on average costs (i.e. the total cost of all R&D,
including failures, divided by the number of products
introduced) and they are often challenged because they
include running costs, overheads, spill-over and inef®-
ciency. The cost of developing one speci®c product may be
signi®cantly lower ± probably US$30±50 million (Love
1997). Moreover, quite often a substantial part of the
®nancing of R&D for important medications comes from
public sources (Attaran 1999).
Today, the pharmaceutical industry is amongst the most
pro®table industrial sectors (Fortune 500 2001), indicating
that the high R&D cost does not necessarily constitute a
barrier for signi®cant returns on investment (O'Brien
1998). Moreover, large companies tend to spend at least as
much on marketing and publicity as they spend on R&D
(Gambardella et al. 2001). Meanwhile, however, the
commercial targets of the R&D-based drug industry have
risen to an ambitious minimum of US$ 200±300 million
sales per developed drug per year. Smaller potential returns
are considered as simply not worth the investment. Thus
the only companies that can afford to invest in R&D have
drifted away from tropical diseases.
Regulatory barriers
The increasingly strict and complex regulations that
govern the development and sale of new drugs contribute
to the high cost and time-consuming nature (8±12 years)
of drug development. While a strong regulatory frame-
work is necessary to protect the health of citizens,
regulatory excesses may inhibit access to drugs, especially
for neglected diseases. In each phase of the development
process, stringent rules apply to guarantee the quality,
ef®cacy and safety of the drug (`Good Laboratory,
Manufacturing and Clinical Practices'). Market author-
ization is only obtained upon full compliance to such
regulations, which can vary from country to country. In an
attempt to establish global standards with respect to the
safety, ef®cacy and quality of pharmaceuticals, the major
drug manufacturing countries (US, European Union and
Japan) agreed upon a common set of guidelines through
the International Conference on Harmonization (ICH) of
regulatory requirements (Of®cial website of ICH: http://
www.ifpma.org/ich1.html). This initiative is a joint
undertaking between industry and regulators. The quality,
ef®cacy and safety requirements that constitute the ICH
guidelines deal speci®cally with drug development in an
af¯uent market, where cost is not a major issue and where
safety is the prime concern. For neglected diseases, cost is a
major issue and the risk-to-bene®t ratio in terms of
quality, ef®cacy and safety should be put into the
perspective of the gross public health failure of having no
treatment at all. However, the ICH recommendations are
being regarded as absolute requirements rather than
guidelines (which they are) (Trouiller et al. 2001). Insist-
ence on compliance with such demanding regulations
further increases the development costs and creates a
major disincentive to small companies from developing
countries or emerging markets trying to enter the market.
In fact, only the large and wealthy companies can comply
with such increasingly demanding regulations. But these
are the companies least interested in neglected diseases
(Wehrli 1997).
Protection of intellectual property
Inventions, such as a new drug or its manufacturing
process, can be protected through patenting. A patent gives
the owner the right to restrain others from producing and
selling the patented product for a given period (usually
20 years) in any country where the patent has been
granted. The rationale behind patent protection is to
stimulate investment in R&D and to promote widespread
dissemination of new and useful technologies, by ensuring
return on investment via temporary market exclusivity.
Northern multinational pharmaceutical companies view
this market monopoly and its consequence, the setting of
the sales price, as a conditio sine qua non to invest in drug
development.
Until recently, the legal basis for patent protection of
products and processes was restricted mainly to the
industrialized world. For this reason, investment in tropical
disease research was considered uneconomical, since
adequate protection of the innovation was not guaranteed
in the countries that would constitute the major market.
The enforcement of the TRIPS agreement (Trade Related
Aspects on Intellectual Property Rights) in the framework
of the World Trade Organization (WTO) should solve the
issue: all WTO member states are required to grant patents
on new drugs and processes for a minimum of 20 years
(http://www.wto.org/wto/intellec/intellec.htm).
But it is uncertain whether stronger patent protection
will promote access to new drugs in low-income countries
(Velasquez & Boulet 1999). In several documented
instances, patent protection has served to prevent patients
from acquiring life-saving drugs because of excessive
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2000). The ongoing trade disputes on the local (and
cheaper) production of life-saving HIV-drugs in South
Africa and Thailand demonstrate clearly that availability
of drugs for those who need them is not a concern of the
northern drug industries, which own the patents. In
addition, stronger patent protection is expected to
adversely affect access to new drugs in countries which
have developed a domestic pharmaceutical industry based
on imitative R&D. The example of the cost-saving
production of praziquantel for schistosomiasis is illustra-
tive: with a stricter patent regime, many would have been
denied this essential drug for many years (Reich &
Govindaraj 1998).
While the pharmaceutical industry argues in favour of a
strengthening and broadening of patent protection as a
stimulus for R&D, there are growing complaints from
within the scienti®c community that patents can become a
barrier to medical progress (Boyce & Coghlan 2000;
Bobrow & Thomas 2001). Patents in science promote
secrecy and strongly hinder free information exchange
between researchers, yet this is the basis for scienti®c
progress. The recent trend in biomedical research to
massive and very broad patenting of both the basic
technologies and the common resources (e.g. the genetic
material) results in a limited `freedom to operate' to
develop new ®ndings into products (Heller & Eisenberg
1998). If new product development requires multiple (and
often costly) licences on existing and exceedingly broad
patents from others, promising discoveries will not even be
pursued. Important discoveries and the resulting potential
bene®ts for society will be lost ± discarded because their
development is either dependent on too many other
patents, or because the discovery cannot be patented
anymore in its own right.
Essential drugs: ordinary consumer goods
or a human right?
While technological advances have increased society's
capacity to control infectious diseases, the position of the
pharmaceutical industry in a highly competitive global
marketplace has turned drugs from a public health tool
into a commodity. It is overwhelmingly clear that if the
decision to invest in R&D is based purely on economic
terms, there is virtually no chance that drugs for neglected
diseases such as trypanosomiasis and onchocerciasis will be
developed. For diseases with a signi®cant market segment
in high-income countries (AIDS and possibly malaria and
tuberculosis), new drugs will be developed, but they will
probably remain too expensive for the millions of patients
in poor countries (until patent protection expires).
Development of essential drugs clearly requires a
different framework. It is the role and duty of national
governments and international bodies, such as the UN
and its agencies, the World Bank and the WTO, to
place global health needs high on the international
political agenda. But this requires political will, a strong
commitment to place health considerations above
economic interests, and the enforcement of rules,
regulations and other mechanisms to stimulate drug
development for Neglected Diseases and secure their
accessibility.
Strategies to stimulate drug development
and ensure access
The attempts of national or international organizations
concerned with public health to promote drug development
for developing countries have thus far been largely
ineffectual (P¯aker & Brudon 1998). An urgent reorien-
tation of policy is warranted. It is essential that the
pharmaceutical industry contributes to the search for
solutions, both at a national and international level. But
industry alone cannot set the rules of the game. In the
ongoing process of creating a new world order, the global
economy must be structured to address the true needs of
society. Four major categories of actions should be
considered.
Essential medicines R&D agenda
Mobilizing existing expertise and knowledge within the
international biomedical research community to address
the speci®c needs of developing countries will require
the establishment and wide dissemination of an essential
medicines R&D agenda which should list and prioritize
the needs, and should specify possible disease-speci®c
factors that need to be taken into account, such as
geographical distribution, existence of different market
segments or the availability of candidate drugs. Clearly,
this R&D agenda will need regular updating with data
from epidemiological surveillance, including the emer-
gence of resistance. At every stage of the R&D process,
the ultimate goal of obtaining effective, affordable and
easy-to-use drugs should guide the R&D choices.
In combination with a speci®c budget allocation for
neglected diseases made by the traditional funding agencies
(such as governments, the European Commission, WHO
and foundations), public research can be redirected to-
wards addressing the most important global health issues.
Government-subsidized industrial R&D can be made
dependent on a commitment to include neglected diseases
in the project portfolio.
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in developing countries
Solutions for tomorrow most likely lie in stimulating and
supporting developing countries to build a viable
R&D-based drug industry that can generate and produce
the drugs they need with adequate quality in collaboration
with the public sector. This will require a serious effort in
capacity-building and technology transfer, along with a
supportive international policy in terms of legal and
regulatory issues (see below) and investments in small or
medium-sized pharmaceutical ®rms in developing coun-
tries. A market that is unattractive to a multinational may
be perfectly viable for a smaller company in a developing
country. Indeed, drug development can become a potential
engine for development. Capacity building and technology
transfer can be promoted via bilateral and multilateral
development co-operation, but priority setting must be
well adapted to the speci®c needs and capabilities of the
concerned countries. Emerging economies may be the ®rst
target of action, and solutions for the poorest countries
may be grafted on successful drug production facilities in
those countries. In time, charity-driven assistance pro-
grammes should be turned into sustainable partnerships
(Donald 1999).
Collaborations between northern universities and uni-
versities in developing countries should be strengthened, as
well as collaborations or partnerships with industry.
Operational research and new studies on existing drugs can
already be conducted in developing countries. This
includes the identi®cation of new indications for existing
drugs, improved formulations or combinations, and the
establishment of simpler treatment protocols. For example,
the treatment of malaria has improved signi®cantly in
recent years as a result of clinical studies on available (old)
drugs. In the long term, capacity should be built to transfer
the results of basic research to the pre-clinical and clinical
phase. Production capacity is already present to a limited
extent, and should be expanded.
Improve legal and regulatory environment
To overcome legal and regulatory barriers towards drug
development for neglected diseases, an adapted interna-
tional legislative and regulatory framework could be
created. It could take the form of an international
`Neglected Diseases Treaty' that is speci®cally designed to
stimulate R&D on effective, affordable and easy-to-use
drugs and vaccines for neglected diseases and also gener-
ates a framework for ensuring access. This treaty should
address the imbalance between rights and obligations
under the present international treaties and agreements
(e.g. TRIPS, Convention of Biological Diversity, Universal
Declaration of Human Rights (UDHR), etc.) and provide
new legal options to make drugs for neglected diseases a
global public good. The treaty could contain speci®c
measures to stimulate industrial involvement in R&D for
neglected diseases [cf. incentives such as tax credits or
reductions as provided in the Orphan Drug Act to
stimulate R&D on rare diseases (Haffner 1999)], but
would go beyond that (Trouiller et al. 1999). It should also
include intellectual property issues (for example conferring
to these drugs the status of global public goods), possibil-
ities for differential pricing and licensing strategies, min-
imal quality, ef®cacy and safety standards based on cost-
effectiveness and a public health approach, and last but not
the least access and affordability criteria. The possible
®nancial incentives should be linked to the ultimate goal of
providing effective medicines for those who need it.
Finance drug development and ensure access
Dedicated money is needed to enable the development of
new drugs for neglected diseases. This will require
persuasive re-prioritizing of budget allocations by all
involved players. Increased ®nancing by national govern-
ments (North and South) and international organizations
(such as the UN and the World Bank) is essential, but must
not be the only source of ®nancing. Public±private
partnerships that combine engagement, ®nance and
expertise from both sectors in addressing public health
priorities should be encouraged. Also, drug development
and production can be promoted as a potential engine for
development in itself. NGOs and private foundations must
also participate in this effort, while the pharmaceutical
industry should be stimulated or directed to invest in drug
development that responds to global health needs. Given
that governments are granting the pharmaceutical industry
a monopoly on the market for medicines, governments
could in return demand that a small percentage of pro®ts
go towards developing essential medicines. Foundations
could be established to fund research and development
activities in accordance with the priorities de®ned in the
essential R&D agenda. They could also provide technical
support, human resources and assist in the technology
transfer process.
In addition to dedicated efforts to stimulate new drug
development, speci®c measures must be taken to ensure
availability and accessibility of essential drugs. For med-
icines that are too expensive for patients in developing
countries but for which there is no market in wealthier
nations, centralized purchases are recommended. Such
medicines include those used to treat trypanosomiasis,
leishmaniasis, meningococcal meningitis and second-line
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governments, international organizations and private
bodies (NGOs and foundations).
When R&D is signi®cant for diseases prevalent in both
the North and South, tiered pricing of the marketed
product tailored to consumer resources seems justi®ed.
Conclusions
Firm and dedicated measures are needed to ensure the
development, availability and accessibility of essential
drugs to combat infectious diseases. Emphasis should be
placed on the target of making these drugs to become
public goods, affordable and easy to use. Solidarity
between North and South, as well as between different
parts of the South, will be indispensable to achieve this
goal. Capacity-building and technology transfer are the key
towards sustainable solutions of the problem.
The scarcity of essential medicines to control infectious
diseases in developing countries demands a signi®cant
reorientation of priorities in drug development and health
policy. Instead of abandoning essential drugs as trivial
consumer goods in a global free market economy, essential
drugs deserve a special status in accordance with their
crucial role in global welfare. It is the duty of society to
provide these basic health tools to as many as possible of
the world's population.
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